Pinnacle Biologics specializes in revitalizing healthcare therapies by promoting, developing and managing innovative approaches to the global commercialization of products in the oncology and specialty areas.
Decemeber 13th, 2011 Treatment of Patients with Malignant Mesothelioma utilizing Photodynamic Therapy with Pinnacle Biologics’ compound PHOTOFRIN® - obtains FDA Orphan Drug Designation.
October 21st, 2011 Pinnacle Biologics, Inc., a privately held specialty bio-pharmaceutical company announced today that it has filed an Orphan Drug Designation (ODD) for their product PHOTOFRIN® (porfimer sodium) as adjuvant therapy to surgery in the treatment of Malignant Pleural Mesothelioma.
September 19th, 2011 Pinnacle Biologics Inc., grants exclusive distribution rights for PHOTOFRIN® and PHOTOBARR® to ALKOPHARMA SA for most of European countries, Middle East and most South East Asian Countries.
March 29th, 2011 Pinnacle Biologics Acquires PHOTOFRIN® and PHOTOBARR®, Novel Photodynamic Therapy for Treating Various Types of Cancer
